Clinical Research Directory

Inclusion Criteria: CLOSED TO ENROLLMENT: INITIAL PILOT COHORT: Participants: 1. Age \>=18 years old. 2. Able to speak and read in English. 3. Have no known cancer risk genetic mutation. 4. Self-identify as Black or African American. 5. Self-report a diagnosis of regional (lymph node positive), advanced, or metastatic prostate cancer per National Comprehensive Cancer Network (NCCN) guidelines. ENROLLING: PART 1: Participants: 1. Age \>=18 years old. 2. Able to speak and read in English. 3. Able to understand study procedures and to comply with them for the entire length of the study. 4. Able to verbally consent. 5. Self-identifies as Black or African-American. 6. Self-reports a diagnosis of regional (lymph node positive), advanced, or metastatic prostate cancer. Note: Participants may or may not have had germline testing in the past, as a range of experiences is valuable for holistic feedback. Providers: 1. Self-identifies as a medical oncologist or genetics provider. 2. Able to speak and read in English. 3. Able to understand study procedures and to comply with them for the entire length of the study. 4. Able to verbally consent. ENROLLING: PART 2: Participants: 1. Age \>=18 years old. 2. Able to speak and read in English. 3. Able to understand study procedures and to comply with them for the entire length of the study. 4. Able to provide written informed consent. 5. Have no known cancer risk genetic mutation. 6. Self-identify as Black or African American. 7. Self-report a diagnosis of regional (lymph node positive), advanced, or metastatic prostate cancer per NCCN guidelines. 8. For patients recruited from the clinic: Presence of an oncology appointment within 3 months where germline testing will be discussed. Exclusion Criteria: CLOSED TO ENROLLMENT: INITIAL PILOT COHORT. 1. Prior germline genetic test. 2. Age \<18 years old. 3. Unable to read or answer forms. ENROLLING: PART 1: 1\. Contraindication to any study-related procedure or assessment. ENROLLING: PART 2: 1. Self-reports prior germline genetic test. 2. Contraindication to any study-related procedure or assessment.